Valrubicin

• Description :

  Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC50s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.

• Product Name Alternative :

  AD-32

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H340, H350, H360

• Target :

  Antibiotic; PKC

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Epigenetics; TGF-beta/Smad

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Valrubicin.html

• Purity :

  99.60

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  CCCCC(OCC([C@]1(O)CC2=C(C(O)=C3C(C4=C(C(C3=C2O)=O)C=CC=C4OC)=O)[C@@H](O[C@H]5C[C@H](NC(C(F)(F)F)=O)[C@H](O)[C@H](C)O5)C1)=O)=O

• Molecular Formula :

  C34H36F3NO13

• Molecular Weight :

  723.64

• Precautions :

  H302, H340, H350, H360

• References & Citations :

  [1]Chuang LF, et al. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32) . Biochem Pharmacol. 1992 Feb 18;43 (4) :865-72.|[2]Wani MK, et al. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2000 Dec;110 (12) :2026-32.|[3]Hauge E, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol. 2012 Aug;167 (2) :288-95.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  PKC

• CAS Number :

  [56124-62-0]